Skip to main content
Exploring the TALAPRO-2 Study of Talazoparib and Enzalutamide in Prostate Cancer: Stephen Freedland, MD, and Neeraj Agarwal, MD
Keira Smith
Expert Analysis
In this interview, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, speaks with Dr. Neeraj Agarwal, Director of the Genitourinary (GU) Medical Oncology Group at Huntsman Cancer Institute, about his recent publication of the TALAPRO-2 study. Dr. Agarwal delves into the results of the trial, which investigated the efficacy of talazoparib plus enzalutamide for first-line metastatic castration-resistant prostate cancer (mCRPC), and their practice-changing significance.
Enzalutamide Approved for Nonmetastatic Castration-Sensitive Prostate Cancer With Biochemical Recurrence: Stephen Freedland, MD
Keira Smith
Expert Analysis
The FDA recently granted approval to enzalutamide (enza) for the treatment of nonmetastatic castration-sensitive prostate cancer (nmCRPC) with biochemical recurrence, based on the results of the phase 3 EMBARK trial. Following the approval, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, co-lead investigator of the trial, sat down to share more about its significance for patients with high-risk prostate cancer and biochemical recurrence.  
Lung Cancer Awareness Month: Global Perspectives on Treatment and Equity With MedNews Week and Oncology Data Advisor
Keira Smith
Expert Analysis
In this Lung Cancer Awareness Month video, members of Oncology Data Advisor and MedNews Week join forces to share global perspectives regarding treatment, equity, and patient advocacy in lung cancer.  
Great American Smokeout: The Link Between Smoking and Prostate Cancer With Stephen Freedland, MD
Keira Smith
Expert Analysis
In honor of the Great American Smokeout, Oncology Data Advisor sat down with Stephen Freedland, MD, the Director of the Center for Integrated Research in Cancer and Lifestyle at Cedars-Sinai Medical Center, to discuss the impact that smoking has on prostate cancer, as well as to help raise awareness around smoking and share resources for those who are trying to quit.  
Pancreatic Cancer Awareness Month: Improving Early Detection With Joseph Kalis, PharmD, BCOP
Keira Smith
Expert Analysis
This November, Oncology Data Advisor is honoring Pancreatic Cancer Awareness Month and helping to raise awareness about early detection in hopes of improving outcomes for patients with this disease. In this interview, Oncology Data Advisor Editorial Board member Joseph Kalis, PharmD, BCOP, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, explains the challenges related to diagnosis and screening, ongoing efforts to develop better detection methods, and messages for both the public and the health care community for maintaining awareness of pancreatic cancer.  
Additional Advances in Advanced Prostate Cancer With Tanya Dorff, MD
Lyn Brook
Expert Analysis
Recently, Tanya Dorff, MD, Division Chief of the Genitourinary Disease Program at City of Hope, served as faculty for i3 Health's CME/NCPD-approved activity, Evolving Treatment Concepts and New Data in Advanced Prostate Cancer. Since recording, a plethora of new data and treatment options have been made available for prostate cancer, as well as add...
Multidisciplinary Task Force: Mitigating Disease Burden and Health Care Disparities in Relapsed/Refractory Multiple Myeloma
Keira Smith
Press
With the complex and rapidly evolving treatment landscape of multiple myeloma, it is vital that clinicians not only understand factors for informing selection of current and emerging combination and sequential therapeutic strategies, but also employ interdisciplinary strategies for reducing disparities in relapsed/refractory multiple myeloma care. ...
Venetoclax for Multiple Myeloma in the Post-CANOVA Era With Rahul Banerjee, MD, FACP, and Andrew Yee, MD
Keira Smith
Expert Analysis
At the recent International Myeloma Society (IMS) Annual Meeting in Athens, Greece, results were presented of the CANOVA study of venetoclax for patients with relapsed/refractory multiple myeloma. After returning from the meeting, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and Oncology Data Advisor Editorial Board Member, and Dr. Andrew Yee, Clinical Director for Multiple Myeloma at Massachusetts General Hospital, sat down to reflect on the surprising results of the trial and its implications for the current and future treatment of patients with t(11;14) multiple myeloma.  
Lung Cancer Awareness Month: A Fellows Forum Panel With Waqas Haque, MD, MPH; Samuel Kareff, MD, MPH; and Matthew Hadfield, DO
Keira Smith
Expert Analysis
On the first day of Lung Cancer Awareness Month, members of Oncology Data Advisor's Editorial Board and Fellows Forum joined forces to share recent advances in lung cancer research and ways to raise awareness of this disease for both the public and the health care community throughout the month of November. Hear unique perspectives from Matthew Hadfield, DO, Hematology/Oncology Fellow at Brown University; Waqas Haque, MD, MPH, Internal Medicine Resident at New York University; and Samuel Kareff, MD, MPH, Hematology-Oncology Fellow at the University of Miami. 
Creating Educational Opportunities During Fellowship: Board Exam Prep, Live Meetings, and Beyond With Samuel Kareff, MD, MPH, and Matthew Hadfield, DO
Keira Smith
Expert Analysis
This Fellows Forum episode features Dr. Samuel Kareff and Dr. Matthew Hadfield in a discussion about unique ways to create educational opportunities during Hematology/Oncology Fellowship, including board exam preparation, methods for teaching residents and other fellows, and the value of live and virtual onsite continuing medical education (CME) me...
Updates on Bispecific Antibodies in Multiple Myeloma From IMS 2023 With Rahul Banerjee, MD, FACP, and Shonali Midha, MD
Keira Smith
Expert Analysis
At this year's International Myeloma Society (IMS) Annual Meeting, Dr. Shonali Midha, Instructor in Medicine at Harvard Medical School, presented real-world data of teclistamab for patients with relapsed/refractory multiple myeloma. After the meeting, Oncology Data Advisor Editorial Board member Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, sat down with Dr. Midha to further discuss teclistamab's efficacy in the real-world setting and other important updates about bispecific antibodies that were presented.  
Reframing the Conversation in Metastatic Breast Cancer With Janie Metsker, RN, BSN, CN-BN
Keira Smith
Expert Analysis
For patients with metastatic breast cancer (MBC), Breast Cancer Awareness Month can sometimes be demoralizing in light of pervasive public messaging about finding a cure and embracing survivorship. In this interview, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke's Koontz Center for Advanced Breast Cancer, shares ways to reframe the conversation in metastatic breast cancer to prioritize shared decision making, patients' individual goals, and redefining hope. Additionally, we hear a message from Justin Bray, a patient with metastatic breast cancer, about the importance for clinicians to form relationships with patients in order to understand and develop the best care for them throughout their journey.  
Real-World Use Patterns, Effectiveness, and Tolerability of Sacituzumab Govitecan for Triple-Negative Breast Cancer With Kevin Kalinsky, MD, MS
Lyn Brook
Expert Analysis
At this year's European Society for Medical Oncology (ESMO) Congress in Madrid, Spain, Dr. Kevin Kalinsky, Director of the Glenn Family Breast Center at Winship Cancer Institute of Emory University, presented the results of real-world use patterns, effectiveness, and tolerability of sacituzumab govitecan for second-line or later treatment of metast...
Additional Advances in Small Cell Lung Cancer Radiotherapy With Henry Park, MD, MPH
Keira Smith
Expert Analysis
Recently, Dr. Henry Park, Chief of Thoracic Radiotherapy at Smilow Cancer Network of Yale School of Medicine, served as faculty for i3 Health's CME/NCPD/CPE–approved activity, Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer (SCLC). This month, numerous updates in the use of radiotherapy for SCLC were presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting. In this interview, Dr. Park outlines the most significant updates presented at ASTRO and how he plans to incorporate them into the treatment of patients with SCLC.  
Self-Management Strategies for Peripheral Neuropathy: A Breast Cancer Awareness Month Interview With Connie Visovsky, PhD, RN, ACNP, FAAN
Keira Smith
Expert Analysis
In this interview for Breast Cancer Awareness Month, Dr. Connie Visovsky, Professor and Endowed Chair in Nursing Science at the University of South Florida, shares her research regarding exercise as a self-management strategy for chemotherapy-induced peripheral neuropathy (CIPN) experienced by patients during breast cancer treatment. Additionally, she gives an update on her presentation from last year's ODACon Breast Cancer Symposium regarding new directions in research for CDK4/6 inhibitors.  
Breast Cancer Awareness Month: Debunking Breast Cancer Myths With Jason Mouabbi, MD
Keira Smith
Expert Analysis
In this interview for Breast Cancer Awareness Month, Dr. Jason Mouabbi, Assistant Professor in the Department of Breast Oncology at the University of Texas MD Anderson Cancer Center, provides insightful answers to frequently asked questions and debunks common myths surrounding breast cancer diagnosis, screening, and treatment.  
Embracing Compassion in Health Care: The Power of Being Present With Marcus Engel, MS, CXCP, CSP
Keira Smith
Expert Analysis
In this interview, Marcus Engel, MS, CXCP, CSP, a renowned health care author and speaker, sat down with Oncology Data Advisor to share his personal experiences of receiving compassion in the health care system, its implication for patient care, and ways that medical professionals can embrace compassion and integrate it into their practice.  
Pink Fund: Providing Financial Assistance During Breast Cancer Treatment With Founder Molly MacDonald
Keira Smith
Expert Analysis
For individuals with breast cancer, financial toxicity is a significant and often overwhelming part of the fight. Pink Fund is an organization which provides 90-day non-medical cost-of-living expenses, including housing, transportation, utilities, and insurance costs, for patients undergoing active treatment for breast cancer, enabling them to focus on healing before returning to the workplace. In this interview, Pink Fund's Founder, Molly MacDonald, shares the story of how she founded the organization, resources for both patients who are experiencing financial toxicity and for clinicians seeking to support their patients, and crucial messages for raising awareness of financial toxicity during cancer treatment.  
The Importance of Exercise for Cancer Survivorship With Nagashree Seetharamu, MD, MBBS
Lyn Brook
Expert Analysis
In this interview, Dr. Nagashree Seetharamu, MD, MBBS, a Professor in the Division of Hematology and Medical Oncology in the Department of Medicine at Hofstra Northwell Health, sat down to discuss the vital role that exercise takes in the cancer treatment and recovery process. As well, she shares advice on why an individualized approach to a patien...
Exploring Educational Opportunities During Hematology/Oncology Fellowship With Matthew Hadfield, DO, and Richa Thakur, MD
Keira Smith
Expert Analysis
In this Oncology Data Advisor Fellows Forum interview, Dr. Matthew Hadfield, Medical Oncology Fellow at Brown University, and Dr. Richa Thakur, Hematology/Oncology Fellow at Northwell Health, explore the different types of educational opportunities available during fellowship, including podcasts and in-person meetings, and strategies for finding th...